Safety and effectiveness of the Colovac anastomosis protection device compared with diverting ileostomy after low anterior resection: protocol for an international, multicentre, prospective, non-randomised comparative study (SAFE-3) - Top-Institutions - MDSpire

Safety and effectiveness of the Colovac anastomosis protection device compared with diverting ileostomy after low anterior resection: protocol for an international, multicentre, prospective, non-randomised comparative study (SAFE-3)

  • By

  • Clément Pastier

  • Patricia Sylla

  • Sang W Lee

  • Antonino Spinelli

  • Niels Komen

  • John Marks

  • Joseph Martz

  • Rebecca Rhee

  • Justin Maykel

  • Jorge Marcet

  • Quentin Denost

  • Karen Zaghiyan

  • Jennifer S Davids

  • Nivedh Paluvoi

  • David Hiller

  • Elisabeth C McLemore

  • Leon Maggiori

  • Andre D’hoore

  • Mehraneh D Jafari

  • Vitaliy Poylin

  • Christopher Jerome Buzas

  • Jean-Jaques Tuech

  • Jérémie H Lefèvre

  • June 12, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Icahn School of Medicine at Mount Sinai / The Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai / The Mount Sinai Hospital

    New York, New York

    Key Differentiators

    • Colorectal Surgery

  • #2

    First Affiliated Hospital of Anhui Medical University
    First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui

    Key Differentiators

    • Colorectal Surgery

  • #3

    Yeungnam University Hospital
    Yeungnam University Hospital

    Daegu, South Korea

    Key Differentiators

    • Colorectal Surgery

  • #4

    Karolinska University Hospital
    Karolinska University Hospital

    Stockholm, Sweden

    Key Differentiators

    • Colorectal Surgery

  • #5

    Amsterdam UMC
    Amsterdam UMC

    Amsterdam, Netherlands

    Key Differentiators

    • Colorectal Surgery

Original Source(s)

Safety and effectiveness of the Colovac anastomosis protection device compared with diverting ileostomy after low anterior resection: protocol for an international, multicentre, prospective, non-randomised comparative study (SAFE-3)

  • by Clément Pastier, Patricia Sylla, Sang W Lee, Antonino Spinelli, Niels Komen, John Marks, Joseph Martz, Rebecca Rhee, Justin Maykel, Jorge Marcet, Quentin Denost, Karen Zaghiyan, Jennifer S Davids, Nivedh Paluvoi, David Hiller, Elisabeth C McLemore, Leon Maggiori, Andre D’hoore, Mehraneh D Jafari, Vitaliy Poylin, Christopher Jerome Buzas, Jean-Jaques Tuech, Jérémie H Lefèvre

  • June 12, 2026

Related Content

Subtype-specific sonographic signatures and clinicopathological features of metaplastic breast cancer: a 50-case cohort study

Durable stable disease and immune activation in metastatic uveal melanoma treated with tebentafusp: case report

ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.

  • July 1, 2026

  • 1 min